To The Moon

The information and materials provided here, whether or not provided on TBI’s Substack (TBI), on third party websites, in marketing materials, newsletters or any form of publication are provided for general information and circulation only.

None of the information contained here constitutes an offer (or solicitation of an offer) to buy or sell any currency, product or financial instrument, to make any investment, or to participate in any particular trading strategy.

TBI does not take into account of your personal investment objectives, specific investment goals, specific needs or financial situation and makes no representation and assumes no liability to the accuracy or completeness of the information provided here. The information and publications are not intended to be and do not constitute financial advice, investment advice, trading advice or any other advice or recommendation of any sort offered or endorsed by TBI. TBI also does not warrant that such information and publications are accurate, up to date or applicable to the circumstances of any particular case. Any expression of opinion (which may be subject to change without notice) is personal to TBI and TBI makes no guarantee of any sort regarding accuracy or completeness of any information or analysis supplied. TBI is not responsible for any loss arising from any investment based on any perceived recommendation, forecast or any other information contained here. The contents of these publications should not be construed as an express or implied promise, guarantee or implication by TBI that you will profit or that losses in connection therewith can or will be limited, from reliance on any information set out here.

Fifth of the week! Let’s review a few more names:

CVS Health Corporation (NYSE: CVS)

CVS has been unable to hold above the 2014 prior ATH of 98.62. It retraced all the way back into the half-yearly level at 43.65 before bouncing back hard into the red resistance trendline.

Recently, CVS lost the rising blue support trendline that was sustaining the run up to the resistance trendline. However, it's still holding the 71.99 yearly level.

If CVS breaks below 71.99, then it's likely to retrace back into the 62.18 Fib level with time.

Otherwise, if CVS breaks above the resistance trendline, it can retest the 84.82 monthly resistance once more and head for the yearly imbalance fill at 86.28.

Humana Inc. (NYSE: HUM)

HUM broke down from its long-term support trendline and is currently consolidating in a descending channel pattern.

Last week, HUM found support at the 176.73 Fib level. Provided that this level holds, HUM can retrace back into the 217.80 yearly level from below, or even as far as the underside of the long-term support trendline.

Otherwise, if HUM breaks below 176.73 or even channel support, it could push into the major half-yearly supports at 152-162.

Note that structural breakdowns have a tendency to be bearish over the longer term, although it’s still possible for there to be upside retracements, or even reversals when using other technical analysis techniques to review the same chart.

Teradyne, Inc. (NASDAQ: TER)

TER is currently trading above its 1.618 Fib extension at 271.57. It also formed a breakaway weekly imbalance at 255-297.

Seeing that TER is currently in price discovery with lower timeframe oscillators in extreme overbought, watch the reaction at 296.50 if TER pulls back. If it breaks below 296.50, then it could retrace back into the 271.57 Fib level.

Otherwise, TER could see continued price discovery into the next Fib level at 437.68.

@TigerWire @TigerStars @TigerEvents @CaptainTiger @MillionaireTiger

$CVS Health(CVS)$ $Humana(HUM)$ $Teradyne(TER)$ $Caterpillar(CAT)$ $Advanced Micro Devices(AMD)$